Identification and validation of prognostic biomarkers in ccRCC: immune-stromal score and survival prediction

Abstract Background The tumor microenvironment (TME) is integral to tumor progression. However, its prognostic implications and underlying mechanisms in clear cell renal cell carcinoma (ccRCC) are not yet fully elucidated. This study aims to examine the prognostic significance of genes associated wi...

Full description

Saved in:
Bibliographic Details
Main Authors: Fang Lyu, Yuxin Zhong, Qingliu He, Wen Xiao, Xiaoping Zhang
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12885-025-13534-0
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832571600564649984
author Fang Lyu
Yuxin Zhong
Qingliu He
Wen Xiao
Xiaoping Zhang
author_facet Fang Lyu
Yuxin Zhong
Qingliu He
Wen Xiao
Xiaoping Zhang
author_sort Fang Lyu
collection DOAJ
description Abstract Background The tumor microenvironment (TME) is integral to tumor progression. However, its prognostic implications and underlying mechanisms in clear cell renal cell carcinoma (ccRCC) are not yet fully elucidated. This study aims to examine the prognostic significance of genes associated with immune-stromal scores and to explore their underlying mechanisms in ccRCC. Methods Data from the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) were subjected to analysis to compute immune and stromal scores utilizing the ESTIMATE algorithm. The weighted gene co-expression network analysis (WGCNA) was employed to identify gene modules associated with these scores. Differentially expressed genes were assessed using the limma package. Prognostic biomarkers were subsequently identified through univariate, LASSO, and multivariate Cox regression analyses, culminating in the development of a risk score model. Gene expression was confirmed in ccRCC cell lines (786-O, Caki-1) and tumor tissues. Functional assays, such as wound healing and Transwell assays, were employed to evaluate tumor invasion and migration. The prognostic accuracy was assessed through ROC curve analysis, and a nomogram integrating risk scores with clinical variables was constructed. Analyses of immune infiltration, human leukocyte antigen (HLA) expression, immune checkpoint expression, immunophenoscore (IPS), tumor immune dysfunction and exclusion (TIDE) scores, and responses to six targeted therapies were conducted across different risk groups. Results Twelve critical prognostic markers, including CAPRIN1, CXCR3, FERMT3, HAPLN3, HBP1, MACF1, MPEG1, OSCAR, STAT1, UBA7, VAMP1, and VSIG4, were identified. The risk score model exhibited a high degree of predictive accuracy for survival outcomes in ccRCC. Immune profiling revealed significant differences in the TME between risk groups, with high-risk patients displaying elevated expression of HLA and immune checkpoints. Drug sensitivity analyses suggested that high-risk patients had a better response to erlotinib, temsirolimus, axitinib, and sunitinib, whereas low-risk patients demonstrated greater sensitivity to pazopanib. Variability in immunotherapy responsiveness between groups was observed based on IPS and TIDE analyses. Conclusion This study highlights the prognostic value and TME-related mechanisms of immune-stromal score signatures in ccRCC, developing a risk score model and nomogram for predicting patient prognosis.
format Article
id doaj-art-9266bcf979ec49efb2bf6c95708a5809
institution Kabale University
issn 1471-2407
language English
publishDate 2025-01-01
publisher BMC
record_format Article
series BMC Cancer
spelling doaj-art-9266bcf979ec49efb2bf6c95708a58092025-02-02T12:28:51ZengBMCBMC Cancer1471-24072025-01-0125111710.1186/s12885-025-13534-0Identification and validation of prognostic biomarkers in ccRCC: immune-stromal score and survival predictionFang Lyu0Yuxin Zhong1Qingliu He2Wen Xiao3Xiaoping Zhang4Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Critical Care Medicine, Zhongnan Hospital of Wuhan UniversityDepartment of Urology, The Second Affiliated Hospital of Fujian Medical UniversityDepartment of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAbstract Background The tumor microenvironment (TME) is integral to tumor progression. However, its prognostic implications and underlying mechanisms in clear cell renal cell carcinoma (ccRCC) are not yet fully elucidated. This study aims to examine the prognostic significance of genes associated with immune-stromal scores and to explore their underlying mechanisms in ccRCC. Methods Data from the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) were subjected to analysis to compute immune and stromal scores utilizing the ESTIMATE algorithm. The weighted gene co-expression network analysis (WGCNA) was employed to identify gene modules associated with these scores. Differentially expressed genes were assessed using the limma package. Prognostic biomarkers were subsequently identified through univariate, LASSO, and multivariate Cox regression analyses, culminating in the development of a risk score model. Gene expression was confirmed in ccRCC cell lines (786-O, Caki-1) and tumor tissues. Functional assays, such as wound healing and Transwell assays, were employed to evaluate tumor invasion and migration. The prognostic accuracy was assessed through ROC curve analysis, and a nomogram integrating risk scores with clinical variables was constructed. Analyses of immune infiltration, human leukocyte antigen (HLA) expression, immune checkpoint expression, immunophenoscore (IPS), tumor immune dysfunction and exclusion (TIDE) scores, and responses to six targeted therapies were conducted across different risk groups. Results Twelve critical prognostic markers, including CAPRIN1, CXCR3, FERMT3, HAPLN3, HBP1, MACF1, MPEG1, OSCAR, STAT1, UBA7, VAMP1, and VSIG4, were identified. The risk score model exhibited a high degree of predictive accuracy for survival outcomes in ccRCC. Immune profiling revealed significant differences in the TME between risk groups, with high-risk patients displaying elevated expression of HLA and immune checkpoints. Drug sensitivity analyses suggested that high-risk patients had a better response to erlotinib, temsirolimus, axitinib, and sunitinib, whereas low-risk patients demonstrated greater sensitivity to pazopanib. Variability in immunotherapy responsiveness between groups was observed based on IPS and TIDE analyses. Conclusion This study highlights the prognostic value and TME-related mechanisms of immune-stromal score signatures in ccRCC, developing a risk score model and nomogram for predicting patient prognosis.https://doi.org/10.1186/s12885-025-13534-0Clear cell renal cell carcinomaImmune scoreStromal scorePrognosisRisk score
spellingShingle Fang Lyu
Yuxin Zhong
Qingliu He
Wen Xiao
Xiaoping Zhang
Identification and validation of prognostic biomarkers in ccRCC: immune-stromal score and survival prediction
BMC Cancer
Clear cell renal cell carcinoma
Immune score
Stromal score
Prognosis
Risk score
title Identification and validation of prognostic biomarkers in ccRCC: immune-stromal score and survival prediction
title_full Identification and validation of prognostic biomarkers in ccRCC: immune-stromal score and survival prediction
title_fullStr Identification and validation of prognostic biomarkers in ccRCC: immune-stromal score and survival prediction
title_full_unstemmed Identification and validation of prognostic biomarkers in ccRCC: immune-stromal score and survival prediction
title_short Identification and validation of prognostic biomarkers in ccRCC: immune-stromal score and survival prediction
title_sort identification and validation of prognostic biomarkers in ccrcc immune stromal score and survival prediction
topic Clear cell renal cell carcinoma
Immune score
Stromal score
Prognosis
Risk score
url https://doi.org/10.1186/s12885-025-13534-0
work_keys_str_mv AT fanglyu identificationandvalidationofprognosticbiomarkersinccrccimmunestromalscoreandsurvivalprediction
AT yuxinzhong identificationandvalidationofprognosticbiomarkersinccrccimmunestromalscoreandsurvivalprediction
AT qingliuhe identificationandvalidationofprognosticbiomarkersinccrccimmunestromalscoreandsurvivalprediction
AT wenxiao identificationandvalidationofprognosticbiomarkersinccrccimmunestromalscoreandsurvivalprediction
AT xiaopingzhang identificationandvalidationofprognosticbiomarkersinccrccimmunestromalscoreandsurvivalprediction